Lose It

Lose It operates as a medically supervised weight loss clinic in Lexington, Kentucky, with a primary focus on metabolic health optimization through pharmaceutical intervention. Under the clinical direction of Joey Creekbaum III, A.P.R.N., the practice delivers structured weight management programs designed for patients who have not achieved sustainable results through diet and exercise modifications alone. The clinic's location in Lexington positions it to serve the Central Kentucky region with in-person consultations that allow for comprehensive metabolic assessment and ongoing monitoring throughout treatment.

The cornerstone of Lose It's clinical approach is its Semaglutide Medical Weight Loss Program, which utilizes this GLP-1 receptor agonist to address weight loss through appetite regulation and improved glycemic control. Semaglutide functions by mimicking the incretin hormone GLP-1, which targets areas of the brain involved in appetite regulation while simultaneously slowing gastric emptying to promote satiety. Joey Creekbaum III structures each patient's semaglutide protocol based on individual metabolic markers, starting dosages, and weight loss objectives. The program includes baseline metabolic panels, body composition analysis, and titration schedules that adjust medication dosing as patients progress through treatment phases. This individualized dosing approach accounts for patient tolerance, side effect management, and the rate of weight reduction to optimize outcomes while minimizing gastrointestinal effects commonly associated with GLP-1 agonist therapy.

Joey Creekbaum III brings advanced practice registered nursing credentials to his role as lead provider, with specialized training in metabolic disorders and pharmaceutical weight management interventions. His clinical model emphasizes the physiological mechanisms underlying weight gain and metabolic dysfunction rather than viewing obesity solely as a behavioral issue. During in-person consultations at the Lexington clinic, Creekbaum conducts thorough evaluations that include medical history review, current medication assessment for potential interactions, screening for contraindications to semaglutide therapy, and discussion of realistic weight loss timelines. His approach integrates patient education about how semaglutide affects hunger hormones, insulin sensitivity, and energy expenditure, ensuring patients understand the biological basis for their treatment rather than simply receiving prescriptions.

Patients beginning treatment at Lose It undergo an initial consultation that establishes baseline metrics including weight, BMI, waist circumference, blood pressure, and relevant laboratory values such as hemoglobin A1C, lipid panels, and thyroid function tests. The semaglutide program typically follows a gradual dose escalation protocol over 16-20 weeks, with patients returning for in-person follow-up visits at scheduled intervals to assess progress, adjust dosing, address side effects, and monitor for any adverse reactions. These follow-up appointments include weight checks, vital sign monitoring, and clinical discussions about appetite changes, energy levels, and any challenges patients encounter during treatment. The structured follow-up schedule allows Creekbaum to identify patients who may need dosage modifications or additional metabolic support to achieve their weight loss goals.

Lose It's requirement for in-person consultations reflects a clinical philosophy that prioritizes direct patient assessment and hands-on metabolic monitoring rather than remote prescribing models. This approach enables Joey Creekbaum III to perform physical examinations, observe patient presentation, and build therapeutic relationships that support long-term weight management success. The Lexington clinic serves patients throughout Fayette County and surrounding Kentucky communities who seek medical weight loss interventions backed by provider oversight and evidence-based peptide therapy. By concentrating specifically on semaglutide rather than offering a broad menu of peptide options, Lose It maintains clinical focus on a single, well-researched intervention with substantial clinical trial data supporting its efficacy for weight reduction and metabolic improvement in appropriate patient populations.